Morgan Stanley’s CAMP4 Therapeutics CAMP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$60.6K Buy
14,992
+3,531
+31% +$14.5K ﹤0.01% 6514
2026
Q2
$50.1K Buy
11,461
+1,956
+21% +$8.43K ﹤0.01% 6510
2026
Q1
$41.9K Sell
9,505
-409
-4% -$1.94K ﹤0.01% 6484
2025
Q4
$60.8K Buy
9,914
+9,911
+330,367% +$42.2K ﹤0.01% 6374
2025
Q3
$9 Sell
3
-1,684
-100% -$3.12K ﹤0.01% 8103
2025
Q2
$2.45K Sell
1,687
-7,285
-81% -$14.5K ﹤0.01% 7182
2025
Q1
$35.9K Sell
8,972
-5,289
-37% -$25.6K ﹤0.01% 6378
2024
Q4
$74.4K Buy
+14,261
New +$117K ﹤0.01% 6161

Other funds holding CAMP

Morgan Stanley's CAMP Position: Q3 2026 in Review

Morgan Stanley increased its CAMP4 Therapeutics (CAMP) stake by 31% in Q3 2026, buying an estimated $14.5K and bringing the position to 14,992 shares worth $60.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6514.

Morgan Stanley first reported a position in CAMP in Q4 2024 and has held it in 8 quarters since. The position peaked at $74.4K in Q4 2024. 69 funds tracked by Wall St. Rank hold CAMP as of Q3 2026.

  • Morgan Stanley held 14,992 shares of CAMP4 Therapeutics worth $60.6K as of Q3 2026.
  • Morgan Stanley bought 3,531 CAMP4 Therapeutics shares in Q3 2026, an estimated $14.5K.
  • CAMP4 Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #6514 holding.
  • Morgan Stanley first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Morgan Stanley's CAMP4 Therapeutics position peaked at $74.4K in Q4 2024.
  • 69 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q3 2026.

Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.